| scholarly article | Q13442814 |
| P50 | author | Eero Pukkala | Q30089946 |
| P2093 | author name string | Wang Z | |
| Schiller J | |||
| Paavonen J | |||
| Dillner J | |||
| Lehtinen M | |||
| Koskela P | |||
| Luostarinen T | |||
| Kibur M | |||
| af Geijerstamm V | |||
| P2860 | cites work | Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas | Q33707499 |
| The role of vaccines in the control of STDs: HPV vaccines. | Q33936363 | ||
| Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. | Q35840539 | ||
| Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers | Q36246275 | ||
| Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays. | Q36545052 | ||
| Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study | Q36597321 | ||
| Data quality and quality control of a population-based cancer registry. Experience in Finland | Q36732856 | ||
| A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. | Q37604389 | ||
| Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer | Q37882175 | ||
| Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior | Q37884955 | ||
| Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. | Q39410042 | ||
| Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages | Q39590904 | ||
| Epidemiology of cervical human papillomavirus infections | Q40763848 | ||
| Low-efficacy HIV vaccines: potential for community-based intervention programmes | Q40923293 | ||
| Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization | Q41203441 | ||
| Development of a hepatitis B vaccine from transformed yeast cells. | Q45016008 | ||
| Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease | Q45091146 | ||
| Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia | Q45763071 | ||
| Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women | Q45766711 | ||
| Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation | Q45771837 | ||
| Evaluation of Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles in an Incident Case-Control Study of Cervical Neoplasia | Q45788312 | ||
| Stability over time of serum antibody levels to human papillomavirus type 16. | Q48023859 | ||
| Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. | Q50551200 | ||
| Estimates of the worldwide incidence of eighteen major cancers in 1985. | Q50609607 | ||
| Natural history of cervicovaginal papillomavirus infection in young women. | Q50909200 | ||
| The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. | Q50995710 | ||
| Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. | Q51020817 | ||
| Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study | Q64134004 | ||
| Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection | Q64893946 | ||
| On sample sizes to estimate the protective efficacy of a vaccine | Q68043021 | ||
| Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes | Q69899836 | ||
| Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction | Q71089044 | ||
| Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer | Q71669731 | ||
| New Epidemiology of Human Papillomavirus Infection and Cervical Neoplasia | Q72019230 | ||
| Identification of human papillomavirus seroconversions | Q72646869 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 13-17 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Sexually Transmitted Infections | Q7458852 |
| P1476 | title | Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination | |
| P478 | volume | 76 |
| Q34477498 | Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands |
| Q44173679 | First-generation vaccines against human papillomavirus |
| Q34394146 | Human papillomavirus: clinical significance and malignant potential |
| Q36615392 | Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk |
| Q33453064 | Nordic Biological Specimen Bank Cohorts as Basis for Studies of Cancer Causes and Control: Quality Control Tools for Study Cohorts with More than Two Million Sample Donors and 130,000 Prospective Cancers |
| Q38397934 | Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers |
| Q50667872 | Prerequisites for human papillomavirus vaccine trial: results of feasibility studies. |
| Q73223002 | Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia |
| Q34089060 | Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection |
Search more.